

CLAIMS

1. An adenovirus expression vector comprising the sequence set forth in nucleotides 1 to 35207 of SEQ ID NO: 19, wherein the vector comprises a Fas-chimera transgene comprising the nucleotide sequence set forth in SEQ ID NO: 9, which is operably linked to a promoter comprising the nucleotide sequence set forth in SEQ ID NO: 18.
2. A pharmaceutical composition comprising the vector of claim 1 and a pharmaceutically acceptable carrier.
3. The pharmaceutical composition of claim 2, wherein the pharmaceutically acceptable carrier is selected from ion exchangers, alumina, aluminum stearate, lecithin, serum proteins, such as human serum albumin, buffer substances such as phosphates, glycine, sorbic acid, potassium sorbate, partial glyceride mixtures of saturated vegetable fatty acids, water, salts or electrolytes, such as protamine sulfate, disodium hydrogen phosphate, potassium hydrogen phosphate, sodium chloride, zinc salts, colloidal silica, magnesium trisilicate, polyvinyl pyrrolidone, cellulose-based substances, polyethylene glycol, sodium carboxymethylcellulose, polyacrylates, waxes, polyethylene-polyoxypropylene block polymers, polyethylene glycol and wool fat.
4. The pharmaceutical composition of claim 2, wherein the composition is formulated in phosphate-buffered saline (PBS) and 10% glycerol.
5. A method of producing the adenovirus expression vector of claim 1, the method comprising transducing a host cell with the adenovirus expression vector and replicating the adenovirus in the host cell.
6. An isolated mammalian cell transfected with the vector of claim 1.
7. The pharmaceutical composition of claim 2, wherein the composition is formulated for administration to a mammal.
8. The pharmaceutical composition of claim 7, wherein the mammal is a human.
9. The pharmaceutical composition of claim 2, wherein the composition is formulated for parenteral administration.
10. The pharmaceutical composition of claim 9, wherein the parenteral administration is intravenous.
11. The pharmaceutical composition of claim 2, wherein the composition is coformulated with one or more additional therapeutic agents.
12. The pharmaceutical composition of claim 2, wherein the vector of the composition is at least about 60% pure, at least about 70% pure, at least about 80% pure, at least about 90% pure, at least about 95% pure, at least about 96% pure, at least about 97% pure, at least about 98% pure, at least

about 99% pure, or about 100% pure.

13. The pharmaceutical composition of claim 2, wherein the composition is formulated by adding saline.

14. The pharmaceutical composition of claim 13, wherein the composition is formulated in a fixed unit dose.

15. The pharmaceutical composition of claim 14, wherein the unit dose is 1×10^{12} virus particles per milliliter.

16. The pharmaceutical composition of claim 4, wherein the composition is formulated in a fixed unit dose.

17. The pharmaceutical composition of claim 16, wherein the unit dose is 1×10^{12} virus particles per milliliter.

18. The pharmaceutical composition of claim 2, wherein the composition is formulated as an aqueous suspension.

19. The pharmaceutical composition of claim 4, wherein the composition is formulated as a single bolus dose, an infusion, or a loading bolus dose.

20. The pharmaceutical composition of claim 13, wherein the composition is formulated as a single bolus dose, an infusion, or a loading bolus dose.

21. The vector of claim 1, wherein the vector is at least 60%, at least 70%, at least 80%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% pure.

22. A pharmaceutical composition comprising the vector of claim 21.

23. The isolated mammalian cell of claim 6, wherein the mammalian cell is a PER.C6 cell.